What's next after metformin? focus on sulphonylurea: add-on or combination therapy
Introduction: The pathophysiology of type 2 diabetes (T2DM) mainly focused on insulin resistance and insulin deficiency over the past decades. Currently, the pathophysiologies expanded to ominous octet and guidelines were updated with newer generation of antidiabetic drug classes. However, many pati...
Saved in:
Main Authors: | Lim PC (Author), Chong CP (Author) |
---|---|
Format: | Book |
Published: |
Centro de Investigaciones y Publicaciones Farmaceuticas,
2015-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical outcomes and health care costs combining metformin with sitagliptin or sulphonylureas or thiazolidinediones in uncontrolled type 2 diabetes patients
by: Degli Esposti L, et al.
Published: (2014) -
Sulphonylurea usage in melioidosis is associated with severe disease and suppressed immune response.
by: Xiang Liu, et al.
Published: (2014) -
Investigation of treatment satisfaction and health-related quality of life after add-on to metformin-based therapy in patients with type 2 diabetes
by: Yu-Wen Chang, et al.
Published: (2023) -
Comparative study on efficacy of empagliflozin versus sitagliptin, as an add-on therapy to metformin in type 2 diabetic patients
by: Harsh Salankar, et al.
Published: (2024) -
Fluoroenesulphonamides: N-sulphonylurea isosteres showing nanomolar selective cancer-related transmembrane human carbonic anhydrase inhibition
by: Benoit Métayer, et al.
Published: (2018)